secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001104659-25-100264
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix and Chiesi receive CHMP negative opinion on every-4-week dosing for Elfabrio in EU
--------------------------------------------------------------------------------

- CHMP issued negative opinion for 2 mg/kg every 4 weeks dosing of Elfabrio (pegunigalsidase alfa) for Fabry disease.
- Currently approved dosing regimen of 1 mg/kg every 2 weeks remains unchanged in the EU.
- Decision based on BRIGHT trial and modeling; data insufficient to conclude similar efficacy.
- Chiesi and Protalix express disappointment but reaffirm commitment to Fabry community.
- No financial guidance or other material impact disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925100264/0001104659-25-100264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925100264/plx-20251017x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer